Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis

被引：1
|
作者：
Waks, A. G. [1 ]
Gharaibeh, M. [2 ]
Sjekloca, N. [3 ]
Poluparthi, N. [2 ]
Shah, A. [2 ]
Bergamaco, E. [4 ]
MacCannell, T. [2 ]
Leung, G. [5 ]
Ntalla, I. [6 ]
Oko-osi, H. [2 ]
Tolaney, S. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Gilead Sci Inc, Dept Hlth Econ & Outcomes Res, Foster City, CA USA
[3] Gilead Sci Europe Ltd, Dept Med Affairs, Stockley Pk, CA USA
[4] Gilead Sci Inc, Dept Med Affairs, Foster City, CA USA
[5] Gilead Sci Inc, Dept Real World Evidence, Foster City, CA USA
[6] Gilead Sci Europe Ltd, Dept Real World Evidence, Stockley Pk, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253P
引用
收藏
页码：S653 / S653
页数：1
相关论文
共 50 条
  • [41] Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2-metastatic breast cancer (mBC) in the US
    Park, Leah
    Thompson, Samantha L.
    Roose, James
    Lu, Yichen
    Chaki, Moumita
    Lam, Clara
    Iorgulescu, Bryan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
  • [43] HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY
    Collin, S.
    Tse, J.
    Shaikh, N. F.
    Near, A.
    Hamilton, E.
    Brufsky, A.
    Gradishar, W.
    Mehta, S.
    Long, G. H.
    Toms, N.
    VALUE IN HEALTH, 2024, 27 (06) : S134 - S134
  • [44] Evolution of prescribing trends for HR+/HER2-metastatic breast cancer (mBC) in a post-CDK4/6i world
    Feinberg, Bruce
    Dokubo, Igoni
    Wojtynek, Jeff
    Kish, Jonathan
    CANCER RESEARCH, 2021, 81 (04)
  • [45] A LONGITUDINAL INVESTIGATION OF THE RELATIONSHIPS BETWEEN PATIENT REPORTED SYMPTOMS AND SURVIVAL AMONG PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) TREATED WITH ABEMACICLIB IN THE PHASE 2 MONARCH 1 TRIAL
    Houghton, K.
    Boye, M. E.
    Price, G. L.
    Stull, D. E.
    Tolaney, S. M.
    VALUE IN HEALTH, 2017, 20 (09) : A413 - A413
  • [46] Real-world predictors of first-line treatment and descriptive outcomes in HR+/HER2-metastatic breast cancer patients in the US
    Downer, M. K.
    Jhaveri, Komal
    Bardia, Aditya
    Loi, Sherene
    Kent, Matthew
    Luhn, Patricia
    Humke, Eric W.
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Identifying drivers of first-line HR+/HER2-metastatic breast cancer treatment choices
    Brufsky, Adam
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Kurosky, Samantha K.
    Arruda, Lillian Shahied
    Heck, Wendy
    Cha-Silva, Ashley S.
    FUTURE ONCOLOGY, 2024, 20 (29) : 2165 - 2177
  • [48] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [50] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345